Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Wei Peng Yong, Felicia SW Teo, Lynette LS Teo, Matthew CH Ng, Tira J. Tan, Su Ying Low, Karmen Wong, Peter Ang, Su Pin Choo, Kim Hua Lee & Soo Chin Lee. (2022) Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody–drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore. Expert Opinion on Drug Metabolism & Toxicology 18:12, pages 805-815.
Read now
Read now
Yi-Pu Zhao & Yong Long. (2022) Pulmonary toxicity in driver gene positive non-small cell lung cancer therapy. Current Medical Research and Opinion 38:8, pages 1369-1378.
Read now
Read now
Jia-Ying Zhou, Si-Yang Liu & Yi-Long Wu. (2020) Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer. Expert Opinion on Drug Safety 19:5, pages 589-599.
Read now
Read now
Articles from other publishers (45)
Jiyoung Jeon, Sun Young Jang, Eun Joo Kwak, Sun Hoe Lee, Joo-Yun Byun, Yu-Yon Kim, Young Gil Ahn, Pargat Singh, Kyeongwon Moon & In Su Kim. (2023) Design and synthesis of 4th generation EGFR inhibitors against human triple (Del19/T790M/C797S) mutation. European Journal of Medicinal Chemistry 261, pages 115840.
Crossref
Crossref
N Jewel Samadder, Nathan Foster, Ryan P McMurray, Carol A Burke, Elena Stoffel, Priyanka Kanth, Rohit Das, Marcia Cruz-Correa, E Vilar, Gautam Mankaney, Navtej Buttar, Selvi Thirumurthi, Danielle K Turgeon, Michael Sossenheimer, Michelle Westover, Ellen Richmond, Asad Umar, Gary Della'Zanna, Luz M Rodriguez, Eva Szabo, David Zahrieh & Paul J Limburg. (2023) Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis. Gut 72:2, pages 256-263.
Crossref
Crossref
Wael A. Alanazi, Hussain N. Alhamami, Ali A. Alshamrani, Faleh Alqahtani, Abdulrahman Alshammari, Khalid Alhazzani & Mohammed Alswayyed. (2023) Valsartan prevents gefitinib-induced lung inflammation, oxidative stress, and alteration of plasma metabolites in rats. Saudi Journal of Biological Sciences 30:2, pages 103522.
Crossref
Crossref
Shu-Chi Tseng, Ho Yun Lee & Mizuki Nishino. (2022) Imaging of Drug-Related Pneumonitis in Oncology. Seminars in Respiratory and Critical Care Medicine 43:06, pages 887-898.
Crossref
Crossref
Noriaki Arakawa, Atsuhito Ushiki, Mitsuhiro Abe, Shinichiro Matsuyama, Yoshinobu Saito, Takeru Kashiwada, Yasushi Horimasu, Akihiko Gemma, Koichiro Tatsumi, Noboru Hattori, Kenji Tsushima, Keiko Miyashita, Kosuke Saito, Ryosuke Nakamura, Takeshi Toyoda, Kumiko Ogawa, Motonobu Sato, Kazuhiko Takamatsu, Kazuhiko Mori, Takayoshi Nishiya, Takashi Izumi, Yasuo Ohno, Yoshiro Saito & Masayuki Hanaoka. (2022) Stratifin as a novel diagnostic biomarker in serum for diffuse alveolar damage. Nature Communications 13:1.
Crossref
Crossref
Xixi Lai & Masoud Najafi. (2022) Redox Interactions in Chemo/Radiation Therapy-induced Lung Toxicity; Mechanisms and Therapy Perspectives. Current Drug Targets 23:13, pages 1261-1276.
Crossref
Crossref
Caicun Zhou & Jinming Yu. (2022) Chinese expert consensus on diagnosis and treatment of radiation pneumonitis. Precision Radiation Oncology 6:3, pages 262-271.
Crossref
Crossref
Paolo Cameli, Paola Faverio, Katia Ferrari, Viola Bonti, Stefania Marsili, Maria Antonietta Mazzei, Francesca Mazzoni, Maurizio Bartolucci, Vieri Scotti, Federica Bertolini, Fausto Barbieri, Cinzia Baldessari, Chiara Veronese, Roberto Boffi, Matteo Brighenti, Diego Cortinovis, Massimo Dominici, Alberto Pesci, Elena Bargagli & Fabrizio Luppi. (2022) Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres. Life 12:8, pages 1149.
Crossref
Crossref
Sawako Kaku, Hidehito Horinouchi, Hirokazu Watanabe, Kan Yonemori, Takuji Okusaka, Narikazu Boku, Naoya Yamazaki, Akira Kawai, Yuichiro Ohe & Masahiko Kusumoto. (2022) Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world. Journal of Cancer Research and Clinical Oncology 148:7, pages 1737-1746.
Crossref
Crossref
Charles Khouri, Julien Mahé, Laura Caquelin, Clara Locher & Fabien Despas. (2022) Pharmacology and pharmacovigilance of protein kinase inhibitors. Therapies 77:2, pages 207-217.
Crossref
Crossref
Bo Ram Yang, Jae‐Young Lee & Myeong Gyu Kim. (2022) The risk of pulmonary adverse drug reactions of rebamipide and other drugs for acid‐related diseases: An analysis of the national pharmacovigilance database in South Korea. Journal of Digestive Diseases 23:2, pages 118-123.
Crossref
Crossref
Tomasz Marjanski, Robert Dziedzic, Anna Kowalczyk & Witold Rzyman. (2021) Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review. International Journal of Molecular Sciences 22:22, pages 12244.
Crossref
Crossref
Gianluca Taronna, Alessandro Leonetti, Filippo Gustavo Dall’Olio, Alessandro Rizzo, Claudia Parisi, Sebastiano Buti, Paola Bordi, Stefano Brocchi, Rita Golfieri, Andrea Ardizzoni, Nicola Sverzellati & Marcello Tiseo. (2021)
Transient asymptomatic pulmonary opacities and interstitial lung disease in
EGFR
-mutated non-small cell lung cancer treated with osimertinib
. Tumori Journal, pages 030089162110478.
Crossref
Crossref
O. D. Ostroumova, A. I. Listratov, A. I. Kochetkov & D. A. Sychev. (2021) Drugs associated with drug-induced interstitial lung diseases. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice:2, pages 39-51.
Crossref
Crossref
Sara Cherri, Silvia Noventa, Martina Fanelli, Giulio Calandra, Tiziana Prochilo, Claudio Bnà, Giordano Savelli & Alberto Zaniboni. (2021) Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era. Cancers 13:5, pages 1052.
Crossref
Crossref
Ahmet M. Ulusan, Praveen Rajendran, Wan Mohaiza Dashwood, Omer F. Yavuz, Sabeeta Kapoor, Trace A. Gustafson, Michelle I. Savage, Powel H. Brown, Shizuko Sei, Altaf Mohammed, Eduardo Vilar & Roderick H. Dashwood. (2021) Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP). Cancer Prevention Research 14:3, pages 325-336.
Crossref
Crossref
Yuan Cheng, Qing Yu, Yan Xiong, Cuiyan Guo & Ligong Nie. (2021) Early‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib. Thoracic Cancer 12:5, pages 690-692.
Crossref
Crossref
Boris Duchemann, Johan Pluvy, Bruno Crestani, Gérard Zalcman & Hilario Nunes. (2021) Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis. European Journal of Cancer 145, pages 179-182.
Crossref
Crossref
Kathryn Long & Karthik Suresh. (2020) Pulmonary toxicity of systemic lung cancer therapy. Respirology 25:S2, pages 72-79.
Crossref
Crossref
Shuang Dong, Chenggang Luo, Xuebo Hu, Jing Zhang, Qian Cai, Yu Qian, Fengming Ran, Wuling Ou, Jun Wang, Qing Huang, Tianhua Ren, Guang Han, Feng Zhang, Wei Wei, Xinjun Liang, Huiting Xu, Sheng Wang, Lulu Shi, Shaozhong Wei & Sheng Hu. (2020) Expert Consensus for Treating Cancer Patients During the Pandemic of SARS-CoV-2. Frontiers in Oncology 10.
Crossref
Crossref
Ruifeng Liu, Shihong Wei, Qiuning Zhang, Xueliang Zhang, Hongtao Luo, Jinhui Tian, Yi Li, Long Ge & Xiaohu Wang. (2019) Epidermal growth factor receptor tyrosine kinase inhibitors combined with thoracic radiotherapy or chemoradiotherapy for advanced or metastatic non-small cell lung cancer: A systematic review and meta-analysis of single-arm trials. Medicine 98:29, pages e16427.
Crossref
Crossref
B. Duchemann, M. Didier, M.-C. Pailler, P.-Y. Brillet, M. Kambouchner, Y. Uzunhan, O. Freynet, K. Chouahnia, L. Zelek & H. Nunes. (2019) Le nivolumab peut-il être utilisé dans les fibroses pulmonaires idiopathiques ?. Revue des Maladies Respiratoires 36:2, pages 209-213.
Crossref
Crossref
Sarah Skeoch, Nicholas Weatherley, Andrew Swift, Alexander Oldroyd, Christopher Johns, Conal Hayton, Alessandro Giollo, James Wild, John Waterton, Maya Buch, Kim Linton, Ian Bruce, Colm Leonard, Stephen Bianchi & Nazia Chaudhuri. (2018) Drug-Induced Interstitial Lung Disease: A Systematic Review. Journal of Clinical Medicine 7:10, pages 356.
Crossref
Crossref
Chong Hyun Suh, Hye Sun Park, Kyung Won Kim, Junhee Pyo, Hiroto Hatabu & Mizuki Nishino. (2018) Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients. Lung Cancer 123, pages 60-69.
Crossref
Crossref
Hansang Lee, Ho Yun Lee, Jong-Mu Sun, Se-Hoon Lee, Youjin Kim, Song Ee Park, Jin Seok Ahn, Keunchil Park & Myung-Ju Ahn. (2018) Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication. Journal of Thoracic Oncology 13:8, pages 1106-1112.
Crossref
Crossref
Youngjoo Lee, Ji-Youn Han, Sung Ho Moon, Byung-Ho Nam, Kun Young Lim, Geon Kook Lee, Heung Tae Kim, Tak Yun, Hye Jin An & Jin Soo Lee. (2017) Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status. Cancer Research and Treatment 49:4, pages 981-989.
Crossref
Crossref
V. Cottin, B. Crestani, J. Cadranel, J.-F. Cordier, S. Marchand-Adam, G. Prévot, B. Wallaert, E. Bergot, P. Camus, J.-C. Dalphin, C. Dromer, E. Gomez, D. Israel-Biet, S. Jouneau, R. Kessler, C.-H. Marquette, M. Reynaud-Gaubert, B. Aguilaniu, D. Bonnet, P. Carré, C. Danel, J.-B. Faivre, G. Ferretti, N. Just, F. Lebargy, B. Philippe, P. Terrioux, F. Thivolet-Béjui, B. Trumbic & D. Valeyre. (2017) French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis – 2017 update. Full-length version. Revue des Maladies Respiratoires 34:8, pages 900-968.
Crossref
Crossref
Benedetta Pellegrino, Francesco Facchinetti, Paola Bordi, Mario Silva, Letizia Gnetti & Marcello Tiseo. (2017) Lung toxicity in non-small cell lung cancer patients exposed to ALK inhibitors: report of a peculiar case and systematic review of the literature. Clinical Lung Cancer.
Crossref
Crossref
V. Cottin, B. Crestani, J. Cadranel, J.-F. Cordier, S. Marchand-Adam, G. Prévot, B. Wallaert, E. Bergot, P. Camus, J.-C. Dalphin, C. Dromer, E. Gomez, D. Israel-Biet, S. Jouneau, R. Kessler, C.-H. Marquette, M. Reynaud-Gaubert, B. Aguilaniu, D. Bonnet, P. Carré, C. Danel, J.-B. Faivre, G. Ferretti, N. Just, F. Lebargy, B. Philippe, P. Terrioux, F. Thivolet-Béjui, B. Trumbic & D. Valeyre. (2017) RETRAIT: Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique–Actualisation 2017. Version longue. Revue des Maladies Respiratoires.
Crossref
Crossref
Liping Lin, Juanjuan Zhao, Ning Kong, Yan He, Jiazhu Hu, Fuxi Huang, Jianjun Han & Xiaolong Cao. (2017) Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors. Oncotarget 8:34, pages 57379-57385.
Crossref
Crossref
Yingtian Wang, Mingzhen Wang, Qiaoxia Wang, Zhiying Geng & Mingxiang Sun. (2017) Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials. Oncotarget 8:17, pages 29406-29415.
Crossref
Crossref
Keita Uchino, Masato Komoda, Junichi Tomomatsu, Takahiro Okamoto, Kiyomi Horiuchi, Akihito Tsuji, Yasuhiro Ito, Takuya Todo, Ki Rito & Shunji Takahashi. (2017) Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Cancer: a Phase I/Ii Open-Label Study. Endocrine Practice 23:2, pages 149-156.
Crossref
Crossref
Shotaro Ide, Noriho Sakamoto, Shintaro Hara, Atsuko Hara, Tomoyuki Kakugawa, Yoichi Nakamura, Yoji Futsuki, Koichi Izumikawa, Yuji Ishimatsu, Katsunori Yanagihara & Hiroshi Mukae. (2017) Interstitial Lung Disease Induced by Pazopanib Treatment. Internal Medicine 56:1, pages 79-83.
Crossref
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
641
693
.
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
561
589
.
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
145
165
.
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
123
144
.
Jian Liu, Lihua Wu, Guolan Wu, Xingjiang Hu, Huili Zhou, Junchun Chen, Meixiang Zhu, Wei Xu, Fenlai Tan, Lieming Ding, Yinxiang Wang & Jianzhong Shentu. (2016) A Phase I Study of the Safety and Pharmacokinetics of Higher‐Dose Icotinib in Patients With Advanced Non‐Small Cell Lung Cancer. The Oncologist 21:11, pages 1294.
Crossref
Crossref
Rashmi R. Shah. (2016) Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas. Drug Safety 39:11, pages 1073-1091.
Crossref
Crossref
Helen Gharwan & Hunter Groninger. (2015) Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nature Reviews Clinical Oncology 13:4, pages 209-227.
Crossref
Crossref
Sang Hoon YooJin Ah RyuSeo Ree KimSu Yun OhGu Sung JungDong Jae LeeBong Gyu KwakYu Hyun NamKyung Hyun KimYoung Jun Yang. (2016) Afatinib-Induced Acute Fatal Pneumonitis in Metastatic Lung Adenocarcinoma. Korean Journal of Family Medicine 37:6, pages 351.
Crossref
Crossref
David Reeves. 2016. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
479
491
.
Jian-Guo Zhou, Xu Tian, Long Cheng, Quan Zhou, Yuan Liu, Yu Zhang, Yu-ju Bai & Hu Ma. (2015) The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib. Medicine 94:40, pages e1719.
Crossref
Crossref
Omar Abdel-Rahman & Hesham Elhalawani. (2015) Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis. Future Oncology 11:7, pages 1109-1122.
Crossref
Crossref
Giulia M. Stella, Claudio Valizia, Michele Zorzetto, Simona Inghilleri, Adele Valentini, Roberto Dore, Sara Colombo, Francesco Valentino, Giulio Orlandoni & Patrizia Morbini. (2015) Unexpected responses to EGFR inhibition in NSCLC. Respiratory Medicine Case Reports 16, pages 32-34.
Crossref
Crossref